See more : Trine II Acquisition Corp. (TRAQ-WT) Income Statement Analysis – Financial Results
Complete financial analysis of Cerus Corporation (CERS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cerus Corporation, a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- Supernova Partners Acquisition Company III, Ltd. (STRE-UN) Income Statement Analysis – Financial Results
- Reliance Capital Limited (RELCAPITAL.NS) Income Statement Analysis – Financial Results
- Lakshmi Electrical Control Systems Limited (LAKSELEC.BO) Income Statement Analysis – Financial Results
- DataVan International Corporation (3521.TWO) Income Statement Analysis – Financial Results
- Kyushu Electric Power Company, Incorporated (KYSEF) Income Statement Analysis – Financial Results
Cerus Corporation (CERS)
About Cerus Corporation
Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 156.37M | 162.05M | 130.86M | 91.92M | 74.65M | 60.91M | 43.57M | 37.18M | 34.22M | 36.50M | 39.66M | 36.70M | 33.04M | 23.11M | 17.98M | 16.51M | 11.04M | 35.58M | 24.37M | 13.91M | 9.67M | 8.49M | 4.54M | 1.85M | 2.40M | 2.90M | 6.90M |
| Cost of Revenue | 69.97M | 74.95M | 63.48M | 41.16M | 33.42M | 31.63M | 22.53M | 20.30M | 23.46M | 21.18M | 22.60M | 20.62M | 18.54M | 12.05M | 12.58M | 9.67M | 5.23M | 1.54M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -634.00K | -600.00K | -700.00K | -700.00K |
| Gross Profit | 86.40M | 87.09M | 67.38M | 50.76M | 41.23M | 29.27M | 21.04M | 16.89M | 10.76M | 15.33M | 17.06M | 16.08M | 14.51M | 11.06M | 5.40M | 6.84M | 5.82M | 34.04M | 24.37M | 13.91M | 9.67M | 8.49M | 4.54M | 2.49M | 3.00M | 3.60M | 7.60M |
| Gross Profit Ratio | 55.25% | 53.75% | 51.49% | 55.23% | 55.23% | 48.06% | 48.29% | 45.42% | 31.44% | 41.99% | 43.01% | 43.82% | 43.91% | 47.87% | 30.04% | 41.43% | 52.66% | 95.67% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 134.25% | 125.00% | 124.14% | 110.14% |
| Research & Development | 67.64M | 64.11M | 63.69M | 64.41M | 60.38M | 42.56M | 33.71M | 31.32M | 25.64M | 21.69M | 15.19M | 7.60M | 7.18M | 5.20M | 6.37M | 10.21M | 14.96M | 29.51M | 24.13M | 27.65M | 52.48M | 56.42M | 48.25M | 34.82M | 22.50M | 29.80M | 19.60M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.84M | 52.41M | 48.75M | 45.99M | 37.73M | 29.97M | 25.67M | 23.05M | 21.58M | 21.87M | 27.16M | 24.58M | 14.01M | 9.58M | 10.23M | 11.02M | 11.35M | 10.17M | 7.16M | 4.80M | 3.80M | 3.20M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 56.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 75.52M | 83.34M | 81.29M | 67.02M | 66.21M | 56.84M | 52.41M | 48.75M | 45.99M | 37.79M | 29.97M | 25.67M | 23.05M | 21.58M | 21.87M | 27.16M | 24.58M | 14.01M | 9.58M | 10.23M | 11.02M | 11.35M | 10.17M | 7.16M | 4.80M | 3.80M | 3.20M |
| Other Expenses | 0.00 | -26.27M | -28.66M | -22.33M | -19.13M | 1.75M | 3.86M | -1.28M | 71.00K | 130.00K | 266.00K | 31.00K | 202.00K | 67.00K | 155.00K | 0.00 | 9.45M | 0.00 | 0.00 | 2.86M | 0.00 | 0.00 | 0.00 | 634.00K | 600.00K | 700.00K | 700.00K |
| Operating Expenses | 115.34M | 121.18M | 116.32M | 109.10M | 107.46M | 84.26M | 78.57M | 78.19M | 71.83M | 59.68M | 45.35M | 33.38M | 30.43M | 26.84M | 28.39M | 37.37M | 48.98M | 43.52M | 33.71M | 37.88M | 63.50M | 67.77M | 58.41M | 42.62M | 27.90M | 34.30M | 23.50M |
| Cost & Expenses | 185.30M | 196.13M | 179.80M | 150.25M | 140.88M | 115.90M | 101.10M | 98.48M | 95.30M | 80.85M | 67.96M | 54.00M | 48.97M | 38.89M | 40.97M | 47.04M | 54.21M | 45.06M | 33.71M | 37.88M | 63.50M | 67.77M | 58.41M | 41.98M | 27.30M | 33.60M | 22.80M |
| Interest Income | 0.00 | 5.83M | 4.92M | 3.75M | 6.07M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 8.39M | 5.83M | 4.92M | 3.75M | 6.07M | 4.01M | 3.02M | 2.45M | 1.71M | 599.00K | 520.00K | 551.00K | 964.00K | 689.00K | 302.00K | 10.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.60M | 4.56M | 4.57M | 4.46M | 2.40M | 1.45M | 1.81M | 1.82M | 202.00K | 202.00K | 202.00K | 202.00K | 922.00K | 845.00K | 915.00K | 651.00K | 774.00K | 716.00K | 652.00K | 2.15M | 3.29M | 2.50M | 1.19M | 634.00K | 600.00K | 700.00K | 700.00K |
| EBITDA | -26.54M | -34.08M | -45.99M | -51.37M | -64.61M | -51.88M | -51.87M | -58.47M | -56.14M | -36.55M | -42.04M | -14.38M | -15.10M | -15.38M | -22.92M | -28.53M | -43.17M | -4.06M | -8.69M | -23.01M | -50.54M | -56.78M | -52.69M | -39.51M | -24.29M | -30.00M | -15.20M |
| EBITDA Ratio | -16.97% | -21.03% | -37.40% | -63.46% | -88.72% | -90.28% | -131.58% | -163.91% | -177.66% | -120.94% | -70.85% | -46.59% | -45.40% | -64.61% | -123.18% | -181.01% | -298.28% | -24.63% | -126.29% | -136.45% | -522.96% | -668.79% | -1,161.74% | -2,133.93% | -1,012.50% | -1,075.86% | -237.68% |
| Operating Income | -30.05M | -34.08M | -48.94M | -58.33M | -66.23M | -54.99M | -57.53M | -61.45M | -61.08M | -44.35M | -28.30M | -17.30M | -15.92M | -15.96M | -23.83M | -30.53M | -43.17M | -9.48M | -9.34M | -26.83M | -53.84M | -59.28M | -53.88M | -40.13M | -24.90M | -30.70M | -15.90M |
| Operating Income Ratio | -19.22% | -21.03% | -37.40% | -63.46% | -88.72% | -90.28% | -132.05% | -165.26% | -178.46% | -121.49% | -71.36% | -47.15% | -48.19% | -69.06% | -132.54% | -184.95% | -390.85% | -26.64% | -38.33% | -192.84% | -557.01% | -698.20% | -1,188.05% | -2,168.18% | -1,037.50% | -1,058.62% | -230.43% |
| Total Other Income/Expenses | -7.27M | -8.26M | -5.12M | -1.24M | -4.76M | -2.35M | 832.00K | -1.28M | 1.54M | 5.94M | -14.82M | 1.63M | -1.06M | -953.00K | -302.00K | 1.35M | 4.07M | 4.70M | 22.41M | -4.33M | -4.43M | 2.09M | 4.61M | 4.10M | 0.00 | 1.20M | 1.20M |
| Income Before Tax | -37.32M | -42.34M | -54.06M | -59.57M | -70.98M | -57.34M | -56.70M | -62.73M | -59.54M | -38.37M | -43.12M | -15.68M | -16.98M | -16.91M | -24.67M | 0.00 | -52.62M | -4.78M | 12.75M | -31.15M | -4.43M | -57.19M | -49.27M | -36.03B | 0.00 | -29.50M | -14.70M |
| Income Before Tax Ratio | -23.87% | -26.13% | -41.31% | -64.81% | -95.09% | -94.13% | -130.14% | -168.71% | -173.97% | -105.12% | -108.73% | -42.72% | -51.39% | -73.18% | -137.21% | 0.00% | -476.42% | -13.43% | 52.31% | -223.95% | -45.86% | -673.64% | -1,086.37% | -1,946,682.93% | 0.00% | -1,017.24% | -213.04% |
| Income Tax Expense | 325.00K | 488.00K | 319.00K | 284.00K | 263.00K | 229.00K | 3.89M | 175.00K | -3.67M | 195.00K | 218.00K | 242.00K | 964.00K | 689.00K | 228.00K | -1.35M | 2.14M | 0.00 | -22.41M | 7.19M | 53.84M | 0.00 | 100.00K | 4.10B | -2.30M | -1.10M | -1.20M |
| Net Income | -37.49M | -42.83M | -54.38M | -59.86M | -71.24M | -57.56M | -60.59M | -62.91M | -55.87M | -38.57M | -43.34M | -15.92M | -16.98M | -16.91M | -24.14M | -29.18M | -45.30M | -4.78M | 13.06M | -31.15M | -58.27M | -57.19M | -49.37M | -36.03M | -22.60M | -29.60M | -14.70M |
| Net Income Ratio | -23.98% | -26.43% | -41.55% | -65.12% | -95.44% | -94.51% | -139.06% | -169.18% | -163.25% | -105.65% | -109.28% | -43.38% | -51.39% | -73.18% | -134.22% | -176.78% | -410.21% | -13.43% | 53.60% | -223.95% | -602.87% | -673.64% | -1,088.58% | -1,946.68% | -941.67% | -1,020.69% | -213.04% |
| EPS | -0.21 | -0.24 | -0.32 | -0.37 | -0.51 | -0.44 | -0.56 | -0.62 | -0.58 | -0.52 | -0.64 | -0.29 | -0.35 | -0.42 | -0.69 | -0.90 | -1.42 | -0.18 | 0.58 | -1.41 | -3.01 | -3.61 | -3.27 | -2.75 | -2.04 | -3.17 | -1.76 |
| EPS Diluted | -0.21 | -0.24 | -0.32 | -0.37 | -0.51 | -0.44 | -0.56 | -0.62 | -0.58 | -0.50 | -0.64 | -0.29 | -0.35 | -0.42 | -0.69 | -0.90 | -1.42 | -0.17 | 0.55 | -1.41 | -3.01 | -3.61 | -3.27 | -2.75 | -2.04 | -3.17 | -1.76 |
| Weighted Avg Shares Out | 180.27M | 176.55M | 171.28M | 163.95M | 139.83M | 130.83M | 108.19M | 101.46M | 96.07M | 74.77M | 67.57M | 54.52M | 48.05M | 40.30M | 34.75M | 32.43M | 31.87M | 26.87M | 22.35M | 22.14M | 19.37M | 15.83M | 15.11M | 13.09M | 11.10M | 9.33M | 8.35M |
| Weighted Avg Shares Out (Dil) | 180.27M | 176.55M | 171.28M | 163.95M | 139.83M | 131.66M | 108.22M | 101.83M | 96.91M | 76.53M | 67.57M | 55.06M | 48.05M | 40.30M | 34.75M | 32.43M | 31.87M | 28.61M | 23.95M | 22.14M | 19.37M | 15.83M | 15.11M | 13.09M | 11.10M | 9.33M | 8.35M |
Cerus Corporation (CERS) Q3 2022 Earnings Call Transcript
Cerus Corporation (NASDAQ:CERS ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Jessica Hanover - Vice President, Corporate Affairs Obi Greenman - President and Chief Executive Officer Vivek Jayaraman - Chief Operating Officer Kevin Green...
Cerus Corporation Announces Third Quarter Financial Results
CONCORD, Calif.
Cerus Corporation Announces Third Quarter Financial Results
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced financial results for the third quarter ended September 30, 2022. Recent developments and highlights include: Third quarter 2022 total revenue of $46.3 million, reflecting a 10% increase over the third quarter of...
Cerus Corporation to Release Third Quarter 2022 Financial Results on November 3, 2022
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its third quarter 2022 financial results will be released on Thursday, November 3, 2022, after the close of the stock market. The Company will host a conference call and webcast at...
Cerus Corporation Announces Workshop and Abstracts at the 2022 AABB Annual Meeting
CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq:CERS) today announced a selection of abstracts and an industry workshop at the 2022 AABB Annual Meeting, taking place in Orlando, FL from October 1 through October 4. This year's AABB Annual Meeting attracts individuals and...
After Plunging 17.6% in 4 Weeks, Here's Why the Trend Might Reverse for Cerus (CERS)
Cerus (CERS) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the...
Down 20.4% in 4 Weeks, Here's Why Cerus (CERS) Looks Ripe for a Turnaround
Cerus (CERS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Source: https://incomestatements.info
Category: Stock Reports